2023
Considerations of Sex and Gender in FDA Tobacco Regulation
Davis D, Krishnan-Sarin S, Mazure C. Considerations of Sex and Gender in FDA Tobacco Regulation. JAMA 2023, 329: 2017-2018. PMID: 37233997, PMCID: PMC11094658, DOI: 10.1001/jama.2023.6803.Peer-Reviewed Original ResearchThe value of teaching the influence of sex and gender on health outcomes
Martin K, Marshall A, Mazure C. The value of teaching the influence of sex and gender on health outcomes. The Lancet Haematology 2023, 10: e318-e319. PMID: 37142343, PMCID: PMC10154001, DOI: 10.1016/s2352-3026(23)00055-8.Peer-Reviewed Original Research
2019
The Influence of Sex and Gender on Health: How Much Is Being Taught in Medical School Curricula?
Thande NK, Wang M, Curlin K, Dalvie N, Mazure CM. The Influence of Sex and Gender on Health: How Much Is Being Taught in Medical School Curricula? Journal Of Women's Health 2019, 28: 1748-1754. PMID: 30864888, DOI: 10.1089/jwh.2018.7229.Peer-Reviewed Original Research
2017
Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey
Smith PH, Zhang J, Weinberger AH, Mazure CM, McKee SA. Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey. Drug And Alcohol Dependence 2017, 178: 485-491. PMID: 28715776, PMCID: PMC6779031, DOI: 10.1016/j.drugalcdep.2017.05.046.Peer-Reviewed Original ResearchConceptsTransdermal nicotine patchUnassisted quit attemptsClinical trial dataTobacco Use SupplementQuit attemptsTrial dataClinical trial findingsReal-world effectivenessSample of smokersGender differencesRelevant gender differencesCessation optionsCessation medicationsCessation pharmacotherapyNicotine patchMedication interactionsSmoking cessationPotential confoundersTrial findingsVareniclineComparative effectivenessPropensity scoreCross-sectional dataWomenMedications
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchMeSH KeywordsFemaleGender IdentityHumansMaleNicotineReceptors, AndrogenSmoking CessationSmoking PreventionSubstance Withdrawal SyndromeConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomenSystematic and Meta-Analytic Review of Research Examining the Impact of Menstrual Cycle Phase and Ovarian Hormones on Smoking and Cessation
Weinberger AH, Smith PH, Allen SS, Cosgrove KP, Saladin ME, Gray KM, Mazure CM, Wetherington CL, McKee SA. Systematic and Meta-Analytic Review of Research Examining the Impact of Menstrual Cycle Phase and Ovarian Hormones on Smoking and Cessation. Nicotine & Tobacco Research 2015, 17: 407-421. PMID: 25762750, PMCID: PMC4429881, DOI: 10.1093/ntr/ntu249.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseHormone levelsOvarian hormonesLuteal phaseSmoking behaviorSearch termsOvarian hormone levelsMenstrual phase effectsCessation-related behaviorsTiming of interventionNegative subjective effectsMenstrual cycle effectsProgesterone administrationFollicular phaseMedication responseQuit ratesTonic cravingInclusion criteriaMenstrual phaseNonsignificant trendSmoking outcomesCycle phaseSmokingSystematic reviewGreater tonic